Pulmonary Manifestations of Rheumatoid Arthritis

Clinics in Chest Medicine

Volumn 31, Issue 3, 2010, Pages 451-478

  Antin Ozerkis, Danielle ^a   Evans, Janine ^a   Rubinowitz, Ami ^a   Homer, Robert J ^a   Matthay, Richard A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Pleuroparenchymal complications; Pulmonary disease; Pulmonary function tests; Rheumatoid arthritis

Indexed keywords

ABATACEPT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GOLD; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AIRWAY OBSTRUCTION; ALLERGIC PNEUMONITIS; AMYLOIDOSIS; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS; CAUSAL ATTRIBUTION; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; COUGHING; CYTOLOGY; DIFFUSE NODULOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHILIA; EPIDEMIOLOGICAL DATA; GOODPASTURE SYNDROME; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RISK; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS PROTEINOSIS; LUNG BIOPSY; LUNG DISEASE; LUNG FUNCTION TEST; LUNG HEMORRHAGE; LUNG LAVAGE; LUNG TOXICITY; MUSCLE WEAKNESS; MYOPATHY; PATHOPHYSIOLOGY; PLEURA BIOPSY; PLEURA DISEASE; PLEURA EFFUSION; PLEURA FLUID; PLEURODESIS; PNEUMOCONIOSIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PULMONARY VASCULAR DISEASE; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; SIDE EFFECT; THORACOCENTESIS; THORACOTOMY; THORAX RADIOGRAPHY; TUBERCULOSIS;

EID: 77955376153     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2010.04.003     Document Type: Review

References (284)

1. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31(3):315-324.
2. Klareskog L., Catrina A.I., Paget S. Rheumatoid arthritis. Lancet 2009, 373(9664):659-672.
3. Gabriel S.E., Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009, 11(3):229.
4. Spector T.D. Rheumatoid arthritis. Rheum Dis Clin North Am 1990, 16(3):513-537.
5. Gabriel S.E., Crowson C.S., Kremers H.M., et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003, 48(1):54-58.
6. Mori S., Cho I., Koga Y., et al. A simultaneous onset of organizing pneumonia and rheumatoid arthritis, along with a review of the literature. Mod Rheumatol 2008, 18(1):60-66.
7. Nannini C., Ryu J.H., Matteson E.L. Lung disease in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20(3):340-346.
8. Saag K.G., Kolluri S., Koehnke R.K., et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum 1996, 39(10):1711-1719.
9. Kinder A.J., Hassell A.B., Brand J., et al. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford) 2005, 44(1):61-66.
10. Ellman P., Ball R.E. Rheumatoid disease with joint and pulmonary manifestations. Br Med J 1948, 2(4583):816-820.
11. Christie G.S. Pulmonary lesions in rheumatoid arthritis. Australas Ann Med 1954, 3(1):49-58.
12. Dixon A.S., Ball J. Honeycomb lung and chronic rheumatoid arthritis; a case report. Ann Rheum Dis 1957, 16(2):241-245.
13. Stack B.H., Grant I.W. Rheumatoid interstitial lung disease. Br J Dis Chest 1965, 59(4):202-211.
14. Frank S.T., Weg J.G., Harkleroad L.E., et al. Pulmonary dysfunction in rheumatoid disease. Chest 1973, 63(1):27-34.
15. Popper M.S., Bogdonoff M.L., Hughes R.L. Interstitial rheumatoid lung disease. A reassessment and review of the literature. Chest 1972, 62(3):243-250.
16. Fewins H.E., McGowan I., Whitehouse G.H., et al. High definition computed tomography in rheumatoid arthritis associated pulmonary disease. Br J Rheumatol 1991, 30(3):214-216.
17. Dawson J.K., Fewins H.E., Desmond J., et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001, 56(8):622-627.
18. Gabbay E., Tarala R., Will R., et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997, 156(2 Pt 1):528-535.
19. Gochuico B.R., Avila N.A., Chow C.K., et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008, 168(2):159-166.
20. Bilgici A., Ulusoy H., Kuru O., et al. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int 2005, 25(6):429-435.
21. Suzuki A., Ohosone Y., Obana M., et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 1994, 21(1):33-36.
22. Turesson C., O'Fallon W.M., Crowson C.S., et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002, 29(1):62-67.
23. Cimmino M.A., Salvarani C., Macchioni P., et al. Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis. Rheumatol Int 2000, 19(6):213-217.
24. King M.F.A.T. Connective tissue diseases. Interstitial lung disease 2003, 535-598. BC Decker Inc, London. T.E. Schwarz (Ed.).
25. Brannan H.M., Good C.A., Divertie M.B., et al. Pulmonary disease associated with rheumatoid arthritis. JAMA 1964, 189:914-918.
26. Gizinski A.M., Mascolo M., Loucks J.L., et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol 2009, 28(5):611-613.
27. Akira M., Sakatani M., Hara H. Thin-section CT findings in rheumatoid arthritis-associated lung disease: CT patterns and their courses. J Comput Assist Tomogr 1999, 23(6):941-948.
28. O'Donnell D.E., Ora J., Webb K.A., et al. Mechanisms of activity-related dyspnea in pulmonary diseases. Respir Physiol Neurobiol 2009, 167(1):116-132.
29. Roschmann R.A., Rothenberg R.J. Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy. Semin Arthritis Rheum 1987, 16(3):174-185.
30. Bjoraker J.A., Ryu J.H., Edwin M.K., et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 157(1):199-203.
31. Chetta A., Aiello M., Foresi A., et al. Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2001, 18(2):170-175.
32. O'Donnell D. Physiology of interstitial lung disease. Interstitial lung disease 2003, BC Decker, Ontario, p. 54--74. M. Schwartz (Ed.).
33. Hughes J.M., Lockwood D.N., Jones H.A., et al. DLCO/Q and diffusion limitation at rest and on exercise in patients with interstitial fibrosis. Respir Physiol 1991, 83(2):155-166.
34. Harris-Eze A.O., Sridhar G., Clemens R.E., et al. Oxygen improves maximal exercise performance in interstitial lung disease. Am J Respir Crit Care Med 1994, 150(6 Pt 1):1616-1622.
35. Tanaka N., Kim J.S., Newell J.D., et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology 2004, 232(1):81-91.
36. Miller W. Diagnostic thoracic imaging 2006, McGraw-Hill, NewYork.
37. Mori S., Cho I., Koga Y., et al. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol 2008, 35(8):1513-1521.
38. Kocheril S.V., Appleton B.E., Somers E.C., et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 2005, 53(4):549-557.
39. Hunninghake G.W., Zimmerman M.B., Schwartz D.A., et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001, 164(2):193-196.
40. Hunninghake G.W., Lynch D.A., Galvin J.R., et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 2003, 124(4):1215-1223.
41. Kim E.J., Collard H.R., King T.E. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009, 136(5):1397-1405.
42. Kim T.S., Lee K.S., Chung M.P., et al. Nonspecific interstitial pneumonia with fibrosis: high-resolution CT and pathologic findings. AJR Am J Roentgenol 1998, 171(6):1645-1650.
43. Kligerman S.J., Groshong S., Brown K.K., et al. Nonspecific interstitial pneumonia: radiologic, clinical, and pathologic considerations. Radiographics 2009, 29(1):73-87.
44. Travis W.D., Hunninghake G., King T.E., et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society Project. Am J Respir Crit Care Med 2008, 177(12):1338-1347.
45. Park J.S., Lee K.S., Kim J.S., et al. Nonspecific interstitial pneumonia with fibrosis: radiographic and CT findings in 7 patients. Radiology 1995, 195(3):645-648.
46. Sumikawa H., Johkoh T., Ichikado K., et al. Nonspecific interstitial pneumonia: histologic correlation with high-resolution CT in 29 patients. Eur J Radiol 2009, 70(1):35-40.
47. Shin K.M., Lee K.S., Chung M.P., et al. Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study. Radiology 2008, 249(1):328-337.
48. Dawson J.K., Fewins H.E., Desmond J., et al. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis 2002, 61(6):517-521.
49. Nagasawa Y., Takada T., Shimizu T., et al. Inflammatory cells in lung disease associated with rheumatoid arthritis. Intern Med 2009, 48(14):1209-1217.
50. Biederer J., Schnabel A., Muhle C., et al. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur Radiol 2004, 14(2):272-280.
51. Costabel U., Guzman J., Bonella F., et al. Bronchoalveolar lavage in other interstitial lung diseases. Semin Respir Crit Care Med 2007, 28(5):514-524.
52. Schnabel A., Richter C., Bauerfeind S., et al. Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 1997, 52(4):377-379.
53. Ramirez P., Valencia M., Torres A. Bronchoalveolar lavage to diagnose respiratory infections. Semin Respir Crit Care Med 2007, 28(5):525-533.
54. Kim D.S. Interstitial lung disease in rheumatoid arthritis: recent advances. Curr Opin Pulm Med 2006, 12(5):346-353.
55. Leslie K.O., Trahan S., Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med 2007, 28(4):369-378.
56. Yousem S.A., Colby T.V., Carrington C.B. Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis 1985, 131(5):770-777.
57. Kim D.S., Yoo B., Lee J.S., et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19(2):121-127.
58. Douglas W.W., Tazelaar H.D., Hartman T.E., et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001, 164(7):1182-1185.
59. Lee H.K., Kim D.S., Yoo B., et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005, 127(6):2019-2027.
60. Visscher D.W., Myers J.L. Histologic spectrum of idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006, 3(4):322-329.
61. Nicholson A.G. Classification of idiopathic interstitial pneumonias: making sense of the alphabet soup. Histopathology 2002, 41(5):381-391.
62. Nicholson A.G., Addis B.J., Bharucha H., et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 2004, 59(6):500-505.
63. van Thiel R.J., van der Burg S., Groote A.D., et al. Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis. Eur Respir J 1991, 4(7):905-911.
64. Ippolito J.A., Palmer L., Spector S., et al. Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis. Semin Arthritis Rheum 1993, 23(1):70-78.
65. Cordier J.F. Cryptogenic organising pneumonia. Eur Respir J 2006, 28(2):422-446.
66. Ulubas B., Sahin G., Ozer C., et al. Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. Clin Rheumatol 2004, 23(3):249-251.
67. Soubrier M., Jeannin G., Kemeny J.L., et al. Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine 2008, 75(3):362-365.
68. Cho SK, Oh IH, Park CK, et al. Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis. Rheumatol Int.
69. White E.S., Tazelaar H.D., Lynch J.P. Bronchiolar complications of connective tissue diseases. Semin Respir Crit Care Med 2003, 24(5):543-566.
70. Hakala M. Poor prognosis in patients with rheumatoid arthritis hospitalized for interstitial lung fibrosis. Chest 1988, 93(1):114-118.
71. Flaherty K.R., Toews G.B., Travis W.D., et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002, 19(2):275-283.
72. Riha R.L., Duhig E.E., Clarke B.E., et al. Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia. Eur Respir J 2002, 19(6):1114-1118.
73. Park J.H., Kim D.S., Park I.N., et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007, 175(7):705-711.
74. Tansey D., Wells A.U., Colby T.V., et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004, 44(6):585-596.
75. Hubbard R., Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 2002, 41(6):676-679.
76. Kim E.J., Elicker B.M., Maldonado F., et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010, 35(6):1322.
77. Chang H.K., Park W., Ryu D.S. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J Korean Med Sci 2002, 17(2):270-273.
78. Gauhar U.A., Gaffo A.L., Alarcon G.S. Pulmonary manifestations of rheumatoid arthritis. Semin Respir Crit Care Med 2007, 28(4):430-440.
79. Kelly C., Saravanan V. Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. Expert Opin Pharmacother 2008, 9(18):3221-3230.
80. Saketkoo L.A., Espinoza L.R. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009, 337(5):329-335.
81. Saketkoo L.A., Espinoza L.R. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med 2008, 168(15):1718-1719.
82. Vassallo R., Matteson E., Thomas C.F. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002, 122(3):1093-1096.
83. Huggett M.T., Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford) 2006, 45(10):1312-1313.
84. Tournadre A., Ledoux-Eberst J., Poujol D., et al. Exacerbation of interstitial lung disease during etanercept therapy: two cases. Joint Bone Spine 2008, 75(2):215-218.
85. Horler A.R., Thompson M. The pleural and pulmonary complications of rheumatoid arthritis. Ann Intern Med 1959, 51:1179-1203.
86. Walker W.C., Wright V. Pulmonary lesions and rheumatoid arthritis. Medicine (Baltimore) 1968, 47(6):501-520.
87. Gotsman I., Goral A., Nusair S. Secondary spontaneous pneumothorax in a patient with pulmonary rheumatoid nodules during treatment with methotrexate. Rheumatology (Oxford) 2001, 40(3):350-351.
88. Lillington G.A., Carr D.T., Mayne J.G. Rheumatoid pleurisy with effusion. Arch Intern Med 1971, 128(5):764-768.
89. Faurschou P., Francis D., Faarup P. Thoracoscopic, histological, and clinical findings in nine cases of rheumatoid pleural effusion. Thorax 1985, 40(5):371-375.
90. Balbir-Gurman A., Yigla M., Nahir A.M., et al. Rheumatoid pleural effusion. Semin Arthritis Rheum 2006, 35(6):368-378.
91. Jurik A.G., Davidsen D., Graudal H. Prevalence of pulmonary involvement in rheumatoid arthritis and its relationship to some characteristics of the patients. A radiological and clinical study. Scand J Rheumatol 1982, 11(4):217-224.
92. Hakala M., Tiilikainen A., Hameenkorpi R., et al. Rheumatoid arthritis with pleural effusion includes a subgroup with autoimmune features and HLA-B8, Dw3 association. Scand J Rheumatol 1986, 15(3):290-296.
93. Baggenstoss A.H., Rosenberg E.F. Visceral lesions associated with chronic infectious (rheumatoid) arthritis. Arch Pathol 1943, 35:503.
94. Graham W.R. Rheumatoid pleuritis. South Med J 1990, 83(8):973-975.
95. Jones F.L., Blodgett R.C. Empyema and rheumatoid pleuropulmonary disease. Ann Intern Med 1978, 89(1):139-140.
96. Dixon W.G., Hyrich K.L., Watson K.D., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69(3):522.
97. Wetter D.A., Davis M.D. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009, 84(11):979-984.
98. Tanoue L.T. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 1998, 19(4):667-685. viii.
99. Allan J.S., Donahue D.M., Garrity J.M. Rheumatoid pleural effusion in the absence of arthritic disease. Ann Thorac Surg 2005, 80(4):1519-1521.
100. Metafratzi Z.M., Georgiadis A.N., Ioannidou C.V., et al. Pulmonary involvement in patients with early rheumatoid arthritis. Scand J Rheumatol 2007, 36(5):338-344.
101. Pritikin J.D., Jensen W.A., Yenokida G.G., et al. Respiratory failure due to a massive rheumatoid pleural effusion. J Rheumatol 1990, 17(5):673-675.
102. Tsai T.H., Yang P.C. Ultrasound in the diagnosis and management of pleural disease. Curr Opin Pulm Med 2003, 9(4):282-290.
103. Ferguson G.C. Cholesterol pleural effusion in rheumatoid lung disease. Thorax 1966, 21(6):577-582.
104. Hillerdal G. Chylothorax and pseudochylothorax. Eur Respir J 1997, 10(5):1157-1162.
105. Lee S.S., Trimble R.B. Rheumatoid arthritis with bloody and cholesterol pleural effusion. Arch Pathol Lab Med 1985, 109(8):769-771.
106. Dieppe P.A. Empyema in rheumatoid arthritis. Ann Rheum Dis 1975, 34(2):181-185.
107. Sahn S.A., Lakshminarayan S., Char D.C. " Silent" empyema in patients receiving corticosteroids. Am Rev Respir Dis 1973, 107(5):873-876.
108. Joseph J., Sahn S.A. Connective tissue diseases and the pleura. Chest 1993, 104(1):262-270.
109. Potts D.E., Willcox M.A., Good J.T., et al. The acidosis of low-glucose pleural effusions. Am Rev Respir Dis 1978, 117(4):665-671.
110. Sahn S.A., Kaplan R.L., Maulitz R.M., et al. Rheumatoid pleurisy. observations on the development of low pleural fluid pH and glucose level. Arch Intern Med 1980, 140(9):1237-1238.
111. Dodson W.H., Hollingsworth J.W. Pleural effusion in rheumatoid arthritis. Impaired transport of glucose. N Engl J Med 1966, 275(24):1337-1342.
112. Wrightson J.M., Stanton A.E., Maskell N.A., et al. Pseudochylothorax without pleural thickening: time to reconsider pathogenesis?. Chest 2009, 136(4):1144-1147.
113. Halla J.T., Schrohenloher R.E., Koopman W.J. Local immune responses in certain extra-articular manifestations of rheumatoid arthritis. Ann Rheum Dis 1992, 51(5):698-701.
114. Soderblom T., Nyberg P., Pettersson T., et al. Pleural fluid beta-2-microglobulin and angiotensin-converting enzyme concentrations in rheumatoid arthritis and tuberculosis. Respiration 1996, 63(5):272-276.
115. Soderblom T., Pettersson T., Nyberg P., et al. High pleural fluid hyaluronan concentrations in rheumatoid arthritis. Eur Respir J 1999, 13(3):519-522.
116. Pettersson T., Ojala K., Weber T.H. Adenosine deaminase in the diagnosis of pleural effusions. Acta Med Scand 1984, 215(4):299-304.
117. Avnon L.S., Abu-Shakra M., Flusser D., et al. Pleural effusion associated with rheumatoid arthritis: what cell predominance to anticipate?. Rheumatol Int 2007, 27(10):919-925.
118. Nosanchuk J.S., Naylor B. A unique cytologic picture in pleural fluid from patients with rheumatoid arthritis. Am J Clin Pathol 1968, 50(3):330-335.
119. Carmichael D.S., Golding D.N. Rheumatoid pleural effusion with " R.A. cells" in the pleural fluid. Br Med J 1967, 2(5555):814.
120. Faurschou P., Faarup P. Granulocytes containing cytoplasmic inclusions in human tuberculous pleuritis. Scand J Respir Dis 1973, 54(6):341-346.
121. Faurschou P., Faarup P. Pleural granulocytes with cytoplasmic inclusions from patients with malignant lung tumours and mesothelioma. Eur J Respir Dis 1980, 61(3):151-155.
122. Engel U., Aru A., Francis D. Rheumatoid pleurisy. Specificity of cytological findings. Acta Pathol Microbiol Immunol Scand A 1986, 94(1):53-56.
123. Sahn S.A. State of the art. The pleura. Am Rev Respir Dis 1988, 138(1):184-234.
124. Yigla M., Simsolo C., Goralnik L., et al. The problem of empyematous pleural effusion in rheumatoid arthritis: report of two cases and review of the literature. Clin Rheumatol 2002, 21(2):180-183.
125. Helmers R., Galvin J., Hunninghake G.W. Pulmonary manifestations associated with rheumatoid arthritis. Chest 1991, 100(1):235-238.
126. Chapman P.T., O'Donnell J.L., Moller P.W. Rheumatoid pleural effusion: response to intrapleural corticosteroid. J Rheumatol 1992, 19(3):478-480.
127. Yarbrough J.W., Sealy W.C., Miller J.A. Thoracic surgical problems associated with rheumatoid arthritis. J Thorac Cardiovasc Surg 1975, 69(3):347-354.
128. Rueth N., Andrade R., Groth S., et al. Pleuropulmonary complications of rheumatoid arthritis: a thoracic surgeon's challenge. Ann Thorac Surg 2009, 88(3):e20-e21.
129. Jones F.L., Blodgett R.C. Empyema in rheumatoid pleuropulmonary disease. Ann Intern Med 1971, 74(5):665-671.
130. Koegelenberg C.F., Diaconi A.H., Bolligeri C.T. Parapneumonic pleural effusion and empyema. Respiration 2008, 75(3):241-250.
131. Montgomery W.W., Perone P.M., Schall L.A. Arthritis of the cricoarytenoid joint. Ann Otol Rhinol Laryngol 1955, 64(4):1025-1033.
132. Lofgren R.H., Montgomery W.W. Incidence of laryngeal involvement in rheumatoid arthritis. N Engl J Med 1962, 267:193-195.
133. Jurik A.G., Pedersen U. Rheumatoid arthritis of the crico-arytenoid and crico-thyroid joints: a radiological and clinical study. Clin Radiol 1984, 35(3):233-236.
134. Lawry G.V., Finerman M.L., Hanafee W.N., et al. Laryngeal involvement in rheumatoid arthritis. A clinical, laryngoscopic, and computerized tomographic study. Arthritis Rheum 1984, 27(8):873-882.
135. Brazeau-Lamontagne L., et al. Cricoarytenoiditis: CT assessment in rheumatoid arthritis. Radiology 1986, 158(2):463-466.
136. Thompson Link D., Charlin B., Levesque R.Y., et al. Cervicomedullary compression: an unrecognized cause of vocal cord paralysis in rheumatoid arthritis. Ann Otol Rhinol Laryngol 1998, 107(6):462-471.
137. Chen J.J., Branstetter B.F., Myers E.N. Cricoarytenoid rheumatoid arthritis: an important consideration in aggressive lesions of the larynx. AJNR Am J Neuroradiol 2005, 26(4):970-972.
138. Segebarth P.B., Limbird T.J. Perioperative acute upper airway obstruction secondary to severe rheumatoid arthritis. J Arthroplasty 2007, 22(6):916-919.
139. Dockery K.M., Sismanis A., Abedi E. Rheumatoid arthritis of the larynx: the importance of early diagnosis and corticosteroid therapy. South Med J 1991, 84(1):95-96.
140. Wattenmaker I., Concepcion M., Hibberd P., et al. Upper-airway obstruction and perioperative management of the airway in patients managed with posterior operations on the cervical spine for rheumatoid arthritis. J Bone Joint Surg Am 1994, 76(3):360-365.
141. Bengtsson M., Bengtsson A. Cricoarytenoid arthritis-a cause of upper airway obstruction in the rheumatoid arthritis patient. Intensive Care Med 1998, 24(6):643.
142. Kolman J., Morris I. Cricoarytenoid arthritis: a cause of acute upper airway obstruction in rheumatoid arthritis. Can J Anaesth 2002, 49(7):729-732.
143. Absalom A.R., Watts R., Kong A. Airway obstruction caused by rheumatoid cricoarytenoid arthritis. Lancet 1998, 351(9109):1099-1100.
144. Miyanohara T., Igarashi T., Suzuki H., et al. Aggravation of laryngeal rheumatoid arthritis after use of a laryngeal mask airway. J Clin Rheumatol 2006, 12(3):142-144.
145. Bandi V., Munnur U., Braman S.S. Airway problems in patients with rheumatologic disorders. Crit Care Clin 2002, 18(4):749-765.
146. Redlund-Johnell I. Upper airway obstruction in patients with rheumatoid arthritis and temporomandibular joint destruction. Scand J Rheumatol 1988, 17(4):273-279.
147. Kumai Y., Murakami D., Masuda M., et al. Arytenoid adduction to treat impaired adduction of the vocal fold due to rheumatoid arthritis. Auris Nasus Larynx 2007, 34(4):545-548.
148. Funk D., Raymon F. Rheumatoid arthritis of the cricoarytenoid joints: an airway hazard. Anesth Analg 1975, 54(6):742-745.
149. Remy-Jardin M., Remy J., Cortet B., et al. Lung changes in rheumatoid arthritis: CT findings. Radiology 1994, 193(2):375-382.
150. Perez T., Remy-Jardin M., Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med 1998, 157(5 Pt 1):1658-1665.
151. Crestani B. The respiratory system in connective tissue disorders. Allergy 2005, 60(6):715-734.
152. McMahon M.J., Swinson D.R., Shettar S., et al. Bronchiectasis and rheumatoid arthritis: a clinical study. Ann Rheum Dis 1993, 52(11):776-779.
153. Toussirot E., Despaux J., Wendling D. Increased frequency of HLA-DRB1*0401 in patients with RA and bronchiectasis. Ann Rheum Dis 2000, 59(12):1002-1003.
154. Snowden N., Moran A., Booth J., et al. Defective antibody production in patients with rheumatoid arthritis and bronchiectasis. Clin Rheumatol 1999, 18(2):132-135.
155. Puechal X., Fajac I., Bienvenu T., et al. Increased frequency of cystic fibrosis deltaF508 mutation in bronchiectasis associated with rheumatoid arthritis. Eur Respir J 1999, 13(6):1281-1287.
156. Hillarby M.C., McMahon M.J., Grennan D.M., et al. HLA associations in subjects with rheumatoid arthritis and bronchiectasis but not with other pulmonary complications of rheumatoid disease. Br J Rheumatol 1993, 32(9):794-797.
157. Kaushik V.V., Hutchinson D., Desmond J., et al. Association between bronchiectasis and smoking in patients with rheumatoid arthritis. Ann Rheum Dis 2004, 63(8):1001-1002.
158. Swinson D.R., Symmons D., Suresh U., et al. Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol 1997, 36(6):689-691.
159. Shadick N.A., Fanta C.H., Weinblatt M.E., et al. Bronchiectasis. A late feature of severe rheumatoid arthritis. Medicine (Baltimore) 1994, 73(3):161-170.
160. Collins R.L., Turner R.A., Johnson A.M., et al. Obstructive pulmonary disease in rheumatoid arthritis. Arthritis Rheum 1976, 19(3):623-628.
161. Klareskog L., Padyukov L., Alfredsson L. Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol 2007, 19(1):49-54.
162. Vergnenegre A., Pugnere N., Antonini M.T., et al. Airway obstruction and rheumatoid arthritis. Eur Respir J 1997, 10(5):1072-1078.
163. Hassan W.U., Keaney N.P., Holland C.D., et al. Bronchial reactivity and airflow obstruction in rheumatoid arthritis. Ann Rheum Dis 1994, 53(8):511-514.
164. Mountz J.D., Turner R.A., Collins R.L., et al. Rheumatoid arthritis and small airways function. Effects of disease activity, smoking, and alpha 1-antitrypsin deficiency. Arthritis Rheum 1984, 27(7):728-736.
165. Padley S.P., Adler B.D., Hansell D.M., et al. Bronchiolitis obliterans: high resolution CT findings and correlation with pulmonary function tests. Clin Radiol 1993, 47(4):236-240.
166. Devouassoux G., Cottin V., Liote H., et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J 2009, 33(5):1053-1061.
167. Kelly K., Hertz M.I. Obliterative bronchiolitis. Clin Chest Med 1997, 18(2):319-338.
168. Geddes D.M., Corrin B., Brewerton D.A., et al. Progressive airway obliteration in adults and its association with rheumatoid disease. Q J Med 1977, 46(184):427-444.
169. Schwarz M.I., Lynch D.A., Tuder R. Bronchiolitis obliterans: the lone manifestation of rheumatoid arthritis?. Eur Respir J 1994, 7(4):817-820.
170. Cooney T.P. Interrelationship of chronic eosinophilic pneumonia, bronchiolitis obliterans, and rheumatoid disease: a hypothesis. J Clin Pathol 1981, 34(2):129-137.
171. Schlesinger C., Veeraraghavan S., Koss M.N. Constructive (obliterative) bronchiolitis. Curr Opin Pulm Med 1998, 4(5):288-293.
172. Penny W.J., Knight R.K., Rees A.M., et al. Obliterative bronchiolitis in rheumatoid arthritis. Ann Rheum Dis 1982, 41(5):469-472.
173. van de Laar M.A., Westermann C.J., Wagenaar S.S., et al. Beneficial effect of intravenous cyclophosphamide and oral prednisone on D-penicillamine-associated bronchiolitis obliterans. Arthritis Rheum 1985, 28(1):93-97.
174. Gerhardt S.G., McDyer J.F., Girgis R.E., et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003, 168(1):121-125.
175. Hayakawa H., Sato A., Imokawa S., et al. Bronchiolar disease in rheumatoid arthritis. Am J Respir Crit Care Med 1996, 154(5):1531-1536.
176. Howling S.J., Hansell D.M., Wells A.U., et al. Follicular bronchiolitis: thin-section CT and histologic findings. Radiology 1999, 212(3):637-642.
177. Sayah A., English J.C. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol 2005, 53(2):191-209. [quiz 210-2].
178. Kaye B.R., Kaye R.L., Bobrove A. Rheumatoid nodules. Review of the spectrum of associated conditions and proposal of a new classification, with a report of four seronegative cases. Am J Med 1984, 76(2):279-292.
179. Gordon D.A., Stein J.L., Broder I. The extra-articular features of rheumatoid arthritis. A systematic analysis of 127 cases. Am J Med 1973, 54(4):445-452.
180. Lowney E.D., Simons H.M. " Rheumatoid" nodules of the skin: their significance as an isolated finding. Arch Dermatol 1963, 88:853-858.
181. Ziff M. The rheumatoid nodule. Arthritis Rheum 1990, 33(6):761-767.
182. Kato H., Yamakawa M., Ogino T. Complement mediated vascular endothelial injury in rheumatoid nodules: a histopathological and immunohistochemical study. J Rheumatol 2000, 27(8):1839-1847.
183. Kuhn K.A., Kulik L., Tomooka B., et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006, 116(4):961-973.
184. Highton J., Hessian P.A., Stamp L. The rheumatoid nodule: peripheral or central to rheumatoid arthritis?. Rheumatology (Oxford) 2007, 46(9):1385-1387.
185. Hessian P.A., Highton J., Kean A., et al. Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma. Arthritis Rheum 2003, 48(2):334-338.
186. Burrows F.G. Pulmonary nodules in rheumatoid disease: a report of two cases. Br J Radiol 1967, 40(472):256-261.
187. Kang H., Baron M. Embolic complications of a mitral valve rheumatoid nodule. J Rheumatol 2004, 31(5):1001-1003.
188. Friedman B.A. Rheumatoid nodules of the larynx. Arch Otolaryngol 1975, 101(6):361-363.
189. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-2001. A 53-year-old woman with arthritis and pulmonary nodules. N Engl J Med 2001, 344(13):997-1004.
190. Baan H., Haagsma C.J., van de Laar M.A. Corticosteroid injections reduce size of rheumatoid nodules. Clin Rheumatol 2006, 25(1):21-23.
191. Voulgari P.V., Papazisi D., Bai M., et al. Laryngeal involvement in rheumatoid arthritis. Rheumatol Int 2005, 25(5):321-325.
192. Lin J., Ziring D., Desai S., et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008, 126(1):13-30.
193. Weinblatt M.E., Abbott G.F., Koreishi A.F. Case records of the Massachusetts General Hospital. Case 13-2009. A 54-year-old woman with respiratory failure and a cavitary lesion in the lung. N Engl J Med 2009, 360(17):1770-1779.
194. Eriksson M. Rheumatoid arthritis as a risk factor for multiple myeloma: a case-control study. Eur J Cancer 1993, 29(2):259-263.
195. Kelly C., Baird G., Foster H., et al. Prognostic significance of paraproteinaemia in rheumatoid arthritis. Ann Rheum Dis 1991, 50(5):290-294.
196. Khurana R., Wolf R., Berney S., et al. Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. J Rheumatol 2008, 35(9):1704-1708.
197. Jolles H., Moseley P.L., Peterson M.W. Nodular pulmonary opacities in patients with rheumatoid arthritis. A diagnostic dilemma. Chest 1989, 96(5):1022-1025.
198. Baruch A.C., Steinbronn K., Sobonya R. Pulmonary adenocarcinomas associated with rheumatoid nodules: a case report and review of the literature. Arch Pathol Lab Med 2005, 129(1):104-106.
199. Wisnieski J.J., Askari A.D. Rheumatoid nodulosis. A relatively benign rheumatoid variant. Arch Intern Med 1981, 141(5):615-619.
200. Toussirot E., Berthelot J.M., Pertuiset E., et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J Rheumatol 2009, 36(11):2421-2427.
201. Patatanian E., Thompson D.F. A review of methotrexate-induced accelerated nodulosis. Pharmacotherapy 2002, 22(9):1157-1162.
202. van Ede A., den Broeder A., Wagenaar M., et al. Etanercept-related extensive pulmonary nodulosis in a patient with rheumatoid arthritis. J Rheumatol 2007, 34(7):1590-1592.
203. Caplan A. Certain unusual radiological appearances in the chest of coal-miners suffering from rheumatoid arthritis. Thorax 1953, 8(1):29-37.
204. Hunninghake G.W., Fauci A.S. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979, 119(3):471-503.
205. Kelly C.A. Rheumatoid arthritis: classical rheumatoid lung disease. Baillieres Clin Rheumatol 1993, 7(1):1-16.
206. Gough J., Rivers D., Seal R.M. Pathological studies of modified pneumoconiosis in coal-miners with rheumatoid arthritis; Caplan's syndrome. Thorax 1955, 10(1):9-18.
207. Otsuki T., Maeda M., Murakami S., et al. Immunological effects of silica and asbestos. Cell Mol Immunol 2007, 4(4):261-268.
208. De Capitani E.M., Schweller M., da Silva C.M., et al. Rheumatoid pneumoconiosis (Caplan's syndrome) with a classical presentation. J Bras Pneumol 2009, 35(9):942-946.
209. Tomioka R., King T.E. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med 1997, 155(3):1011-1020.
210. Blancas R., Moreno J.L., Martin F., et al. Alveolar-interstitial pneumopathy after gold-salts compounds administration, requiring mechanical ventilation. Intensive Care Med 1998, 24(10):1110-1112.
211. Zitnik R.J., Cooper J.A. Pulmonary disease due to antirheumatic agents. Clin Chest Med 1990, 11(1):139-150.
212. Goodwin S.D., Glenny R.W. Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and food and drug administration adverse drug reaction reports. Arch Intern Med 1992, 152(7):1521-1524.
213. Parry S.D., Barbatzas C., Peel E.T., et al. Sulphasalazine and lung toxicity. Eur Respir J 2002, 19(4):756-764.
214. Woltsche M., Woltsche-Kahr I., Roeger G.M., et al. Sulfasalazine-induced extrinsic allergic alveolitis in a patient with psoriatic arthritis. Eur J Med Res 2001, 6(11):495-497.
215. Kremer J.M., Alarcon G.S., Weinblatt M.E., et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997, 40(10):1829-1837.
216. Alarcon G.S., Kremer J.M., Macaluso M., et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997, 127(5):356-364.
217. Saravanan V., Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45(7):787-789.
218. Cannon G.W. Methotrexate pulmonary toxicity. Rheum Dis Clin North Am 1997, 23(4):917-937.
219. Schnabel A., Dalhoff K., Bauerfeind S., et al. Sustained cough in methotrexate therapy for rheumatoid arthritis. Clin Rheumatol 1996, 15(3):277-282.
220. Fuhrman C., Parrot A., Wislez M., et al. Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis. Am J Respir Crit Care Med 2001, 164(7):1186-1191.
221. Chikura B., Sathi N., Lane S., et al. Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology (Oxford) 2008, 47(11):1647-1650.
222. Imokawa S., Colby T.V., Leslie K.O., et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000, 15(2):373-381.
223. Ito S., Sumida T. Interstitial lung disease associated with leflunomide. Intern Med 2004, 43(12):1103-1104.
224. Kamata Y., Nara H., Kamimura T., et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 2004, 43(12):1201-1204.
225. Suissa S., Hudson M., Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006, 54(5):1435-1439.
226. Sawada T., Inokuma S., Sato T., et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 2009, 48(9):1069-1072.
227. Chikura B., Lane S., Dawson J.K. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford) 2009, 48(9):1065-1068.
228. Kelly C. Leflunomide and the lung. Rheumatology (Oxford) 2009, 48(9):1017-1018.
229. Rozin A., Yigla M., Guralnik L., et al. Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy. Clin Rheumatol 2006, 25(3):384-388.
230. Wardwell N.R., Miller R., Ware L.B. Pulmonary alveolar proteinosis associated with a disease-modifying antirheumatoid arthritis drug. Respirology 2006, 11(5):663-665.
231. Carloni A., Piciucchi S., Giannakakis K., et al. Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis. J Thorac Imaging 2008, 23(1):57-59.
232. Villeneuve E., St-Pierre A., Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol 2006, 33(6):1189-1193.
233. Takeuchi T., Tatsuki Y., Nogami Y., et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67(2):189-194.
234. Wolfe F., Caplan L., Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 2007, 36(3):172-178.
235. Antoniou K.M., Mamoulaki M., Malagari K., et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007, 25(1):23-28.
236. Furst D.E., Keystone E.C., Kirkham B., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008, 67(Suppl 3):iii2-25.
237. Weinblatt M., Combe B., Covucci A., et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006, 54(9):2807-2816.
238. Baum J. Infection in rheumatoid arthritis. Arthritis Rheum 1971, 14(1):135-137.
239. Walker W.C. Pulmonary infections and rheumatoid arthritis. Q J Med 1967, 36(142):239-251.
240. Smitten A.L., Choi H.K., Hochberg M.C., et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008, 35(3):387-393.
241. Doran M.F., Crowson C.S., Pond G.R., et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002, 46(9):2287-2293.
242. Mitchell D.M., Spitz P.W., Young D.Y., et al. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986, 29(6):706-714.
243. Myllykangas-Luosujarvi R., Aho K., Kautiainen H., et al. Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995, 13(2):149-153.
244. Doran M.F., Gabriel S.E. Infections in rheumatoid arthritis-a new phenomenon?. J Rheumatol 2001, 28(9):1942-1943.
245. Saag K.G., Koehnke R., Caldwell J.R., et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994, 96(2):115-123.
246. Wolfe F., Caplan L., Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006, 54(2):628-634.
247. Boerbooms A.M., Kerstens P.J., van Loenhout J.W., et al. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995, 24(6):411-421.
248. LeMense G.P., Sahn S.A. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 1994, 150(1):258-260.
249. Bernatsky S., Hudson M., Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007, 46(7):1157-1160.
250. Coyne P., Hamilton J., Heycock C., et al. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol 2007, 34(9):1832-1836.
251. McLean-Tooke A., Aldridge C., Waugh S., et al. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?. Rheumatology (Oxford) 2009, 48(8):867-871.
252. Oien K.A., Black A., Hunter J.A., et al. Pneumocystis carinii pneumonia in a patient with rheumatoid arthritis, not on immunosuppressive therapy and in the absence of human immunodeficiency virus infection. Br J Rheumatol 1995, 34(7):677-679.
253. Khraishi M. Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl 2009, 82:25-32.
254. Martin-Mola E., Balsa A. Infectious complications of biologic agents. Rheum Dis Clin North Am 2009, 35(1):183-199.
255. Askling J., Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20(2):138-144.
256. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295(19):2275-2285.
257. Listing J., Strangfeld A., Kary S., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52(11):3403-3412.
258. Winthrop K.L. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006, 2(11):602-610.
259. Askling J., Fored C.M., Brandt L., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007, 66(10):1339-1344.
260. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345(15):1098-1104.
261. Centers for Disease Control and Prevention (CDC) Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004, 53(30):683-686.
262. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005, 52(6):1766-1772.
263. Schwarz M.I., Zamora M.R., Hodges T.N., et al. Isolated pulmonary capillaritis and diffuse alveolar hemorrhage in rheumatoid arthritis and mixed connective tissue disease. Chest 1998, 113(6):1609-1615.
264. Ioachimescu O.C., Stoller J.K. Diffuse alveolar hemorrhage: diagnosing it and finding the cause. Cleve Clin J Med 2008, 75(4):258. [260, 264-5 passim].
265. Panagi S., Palka W., Korelitz B.I., et al. Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease. Inflamm Bowel Dis 2004, 10(3):274-277.
266. Heresi G.A., Farver C.F., Stoller J.K. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 2008, 76(4):449-453.
267. Hassoun P.M. Pulmonary arterial hypertension complicating connective tissue diseases. Semin Respir Crit Care Med 2009, 30(4):429-439.
268. Askling J. Malignancy and rheumatoid arthritis. Curr Rheumatol Rep 2007, 9(5):421-426.
269. Smitten A.L., Simon T.A., Hochberg M.C., et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008, 10(2):R45.
270. Baecklund E., Iliadou A., Askling J., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006, 54(3):692-701.
271. Kallberg H. Rheumatoid arthritis and lung cancer: you probably heard it before. J Rheumatol 2008, 35(9):1695-1696.
272. Askling J., van Vollenhoven R.F., Granath F., et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?. Arthritis Rheum 2009, 60(11):3180-3189.
273. Chatterjee S., Kupsky W.J. Severe proximal myopathy and mononeuritis multiplex in rheumatoid arthritis: manifestations of rheumatoid vasculitis. J Clin Rheumatol 2005, 11(1):50-55.
274. Hakkinen A. Effectiveness and safety of strength training in rheumatoid arthritis. Curr Opin Rheumatol 2004, 16(2):132-137.
275. Halla J.T., Koopman W.J., Fallahi S., et al. Rheumatoid myositis. Clinical and histologic features and possible pathogenesis. Arthritis Rheum 1984, 27(7):737-743.
276. Miro O., Pedrol E., Casademont J., et al. Muscle involvement in rheumatoid arthritis: clinicopathological study of 21 symptomatic cases. Semin Arthritis Rheum 1996, 25(6):421-428.
277. Abdel-Hamid H., Oddis C.V., Lacomis D. Severe hydroxychloroquine myopathy. Muscle Nerve 2008, 38(3):1206-1210.
278. Schakman O., Gilson H., Thissen J.P. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008, 197(1):1-10.
279. Strohl K.P., Feldman N.T., Ingram R.H. Apical fibrobullous disease with rheumatoid arthritis. Chest 1979, 75(6):739-741.
280. Yue C.C., Park C.H., Kushner I. Apical fibrocavitary lesions of the lung in rheumatoid arthritis. Report of two cases and review of the literature. Am J Med 1986, 81(4):741-746.
281. Calatayud J., Candelas G., Gomez A., et al. Nodular pulmonary amyloidosis in a patient with rheumatoid arthritis. Clin Rheumatol 2007, 26(10):1797-1798.
282. Tokunaga T., Takeda S., Sawabata N., et al. Nodular pulmonary amyloidosis. Jpn J Thorac Cardiovasc Surg 2006, 54(9):399-401.
283. Sumiya M., Ohya N., Shinoura H., et al. Diffuse interstitial pulmonary amyloidosis in rheumatoid arthritis. J Rheumatol 1996, 23(5):933-936.
284. Turkstra F., Rinkel R.N., Biermann H., et al. Tracheobronchomalacia due to amyloidosis in a patient with rheumatoid arthritis. Clin Rheumatol 2008, 27(6):807-808.